Skip to main content
. Author manuscript; available in PMC: 2018 Jan 11.
Published in final edited form as: FEBS J. 2017 Jan 18;284(3):451–465. doi: 10.1111/febs.13992

Fig. 3.

Fig. 3

Pioglitazone inhibition of pyruvate oxidation does not require the MPC proteins. (A, B) Representative western blot (A) and densitometry quantification (B) of MPC1 and MPC2 protein expression, normalized to GAPDH, in H4IIE cells following siRNA knockdown of each protein. (C) Rate of 14C-pyruvate oxidation in siSCR or siMPC2 H4IIE cells treated with either VEH, PIO (10 μM), or UK (5 μM). **P < 0.01, ***P < 0.001 vs VEH; ^P < 0.05, ^^P < 0.01 vs siSCR. (D) Rate of pyruvate- or glutamate-driven ATP synthesis in mitochondria isolated from siSCR or siMPC2 H4IIE cells. **P < 0.01 vs siSCR. (E, F) Percentage inhibition of pyruvate-driven ATP synthesis by indicated concentrations of PIO or UK in mitochondria isolated from siSCR or siMPC2 H4IIE cells. *P < 0.05, **P < 0.01, ***P < 0.001 vs previous PIO concentration; †P < 0.05 vs siSCR. Values are mean ± SEM of ≥3 independent experiments.